At the Kaplan–Meier analysis, PD-1+ patients (26%) respect to PD-1− (66%; p < 0.01), PD-L1+ patients respect to PD-L1− (71%; p < 0.01) and cAMP+ (30%) patients respect to cAMP− (62%; p = 0.04) had worse 3-years cancer-specific survival. The gene discussed is CD274; the disease is cancer.